Manager TitleAgeSince
President - 2025-07-29
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
-0.53%-3.95%+55.23%+152.74% 1,030B
+0.21%-2.68%+55.61%+53.02% 617B
-2.51%-3.25%+32.76%+67.76% 455B
+0.06%+1.17%+36.21%+31.25% 350B
-0.14%-0.83%+33.24%+40.28% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+2.43%+30.52%+64.49% 209B
-0.82%+0.70%+15.96%+71.01% 163B
Average -0.93%+4.83%+29.30%+50.31% 401.41B
Weighted average by Cap. -0.95%+4.87%+38.47%+72.84%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock